Venrock Healthcare Capital Partners III, L.P. buys $644,711 of Lycia Therapeutics, Inc. (LYCA) as a 10% owner
After the purchase, the filing lists 6,850,237 shares held.
A Form 4 filed on Oct 30 shows Venrock Healthcare Capital Partners III, L.P., a holder of more than 10% of Lycia Therapeutics, Inc., buying 25,004 shares worth $644,711 between Oct 28 and Oct 30, at about $25.78 each.
The purchase was made in the open market, not through an award, an option exercise or a plan. After the trade, the filing lists 6,850,237 shares held.
The trade was reported within two business days, as Section 16 requires.
Figures come from the Form 4 filed with the SEC; the table lists the open-market rows this article covers.
| Company | Lycia Therapeutics, Inc. (LYCA) |
|---|---|
| Insider | Venrock Healthcare Capital Partners III, L.P. |
| Role | 10% owner |
| Transaction | Open-market purchase (code P) |
| Shares | 25,004 |
| Average price | $25.78 |
| Value | $644,711 |
| Trade dates | Oct 28 to Oct 30, 2026 |
| Filed with the SEC | Oct 30, 2026, 7:25 PM ET |
| Shares held after | 6,850,237 |
| Ownership | Indirect |
| Rule 10b5-1 plan | Not marked in the filing |
See the full details of this insider trade
See more large insider purchases · See all insider activity at Lycia Therapeutics, Inc.
Source: SEC Form 4. Information only, not investment advice. Not affiliated with or endorsed by the U.S. Securities and Exchange Commission.